Tags

Type your tag names separated by a space and hit enter

Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?
Int Clin Psychopharmacol. 2018 01; 33(1):56-58.IC

Abstract

Dopamine agonists have been associated with an increased risk of developing impulse control disorders (ICDs). The US Food and Drug Administration (FDA) issued a safety warning in 2016 of a possible association between ICDs and aripiprazole. Recently, one large epidemiological study has confirmed this risk. In the present study, we aim to determine whether the safety signal of ICDs associated with aripiprazole detected by the FDA is replicated in the European pharmacovigilance database (EudraVigilance). We searched for all suspected spontaneous cases of ICDs associated with aripiprazole in EudraVigilance up to 23 February 2017. To assess the association between ICD cases and each dopamine agonist drug, we calculated the proportional reporting ratios (PRRs). Among 4 905 110 events of all types recorded in EudraVigilance, we found 160 cases of ICDs associated with aripiprazole. Aripiprazole fulfilled the criteria to generate a safety signal; PRR (95% confidence interval): 16.39 (13.97-19.24). Notably, the association seemed the strongest for the depot formulation of aripiprazole; PRR (95% confidence interval): 27.13 (17.22-42.75). Our analysis of the data contained in EudraVigilance confirms the safety signal detected last year by the FDA. Interestingly, for the first time, we show that the association seems the strongest for the intramuscular depot formulation of aripiprazole.

Authors+Show Affiliations

Pharmacy Service, Araba Mental Health Network.Internal Medicine Service, Araba Mental Health Network, Vitoria-Gasteiz, Alava Province.Psychiatry Service, Bizkaia Mental Health Network, Portugalete.Pharmacy Service, Alto Deba Integrated Health Care, Arrasate, Gipuzkoa Province.Basque Pharmacovigilance Unit, Galdakao-Usánsolo Hospital, Galdakao, Bizkaia Province.Basque Pharmacovigilance Unit, Galdakao-Usánsolo Hospital, Galdakao, Bizkaia Province. Department of Pharmacology, School of Medicine and Nursing, University of the Basque Country, Leioa, Spain.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28777129

Citation

Lertxundi, Unax, et al. "Aripiprazole and Impulse Control Disorders: Higher Risk With the Intramuscular Depot Formulation?" International Clinical Psychopharmacology, vol. 33, no. 1, 2018, pp. 56-58.
Lertxundi U, Hernandez R, Medrano J, et al. Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation? Int Clin Psychopharmacol. 2018;33(1):56-58.
Lertxundi, U., Hernandez, R., Medrano, J., Domingo-Echaburu, S., Garcia, M., & Aguirre, C. (2018). Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation? International Clinical Psychopharmacology, 33(1), 56-58. https://doi.org/10.1097/YIC.0000000000000194
Lertxundi U, et al. Aripiprazole and Impulse Control Disorders: Higher Risk With the Intramuscular Depot Formulation. Int Clin Psychopharmacol. 2018;33(1):56-58. PubMed PMID: 28777129.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation? AU - Lertxundi,Unax, AU - Hernandez,Rafael, AU - Medrano,Juan, AU - Domingo-Echaburu,Saioa, AU - Garcia,Montserrat, AU - Aguirre,Carmelo, PY - 2017/8/5/pubmed PY - 2018/7/19/medline PY - 2017/8/5/entrez SP - 56 EP - 58 JF - International clinical psychopharmacology JO - Int Clin Psychopharmacol VL - 33 IS - 1 N2 - Dopamine agonists have been associated with an increased risk of developing impulse control disorders (ICDs). The US Food and Drug Administration (FDA) issued a safety warning in 2016 of a possible association between ICDs and aripiprazole. Recently, one large epidemiological study has confirmed this risk. In the present study, we aim to determine whether the safety signal of ICDs associated with aripiprazole detected by the FDA is replicated in the European pharmacovigilance database (EudraVigilance). We searched for all suspected spontaneous cases of ICDs associated with aripiprazole in EudraVigilance up to 23 February 2017. To assess the association between ICD cases and each dopamine agonist drug, we calculated the proportional reporting ratios (PRRs). Among 4 905 110 events of all types recorded in EudraVigilance, we found 160 cases of ICDs associated with aripiprazole. Aripiprazole fulfilled the criteria to generate a safety signal; PRR (95% confidence interval): 16.39 (13.97-19.24). Notably, the association seemed the strongest for the depot formulation of aripiprazole; PRR (95% confidence interval): 27.13 (17.22-42.75). Our analysis of the data contained in EudraVigilance confirms the safety signal detected last year by the FDA. Interestingly, for the first time, we show that the association seems the strongest for the intramuscular depot formulation of aripiprazole. SN - 1473-5857 UR - https://www.unboundmedicine.com/medline/citation/28777129/Aripiprazole_and_impulse_control_disorders:_higher_risk_with_the_intramuscular_depot_formulation L2 - https://doi.org/10.1097/YIC.0000000000000194 DB - PRIME DP - Unbound Medicine ER -